Nanocarrier based active targeting strategies against erythrocytic stage of malaria.

The Global Technical Strategy for Malaria 2016–2030 aims to achieve a 90% reduction in malaria cases, and strategic planning and execution are crucial for accomplishing this target. This review aims to understand the complex interaction between erythrocytic receptors and parasites and to use this knowledge to actively target the erythrocytic stage of malaria. The review provides insight into the malaria life cycle, which involves various receptors such as glycophorin A, B, C, and D (GPA/B/C/D), complement receptor 1, basigin, semaphorin 7a, Band 3/ GPA, Kx, and heparan sulfate proteoglycan for parasite cellular binding and ingress in the erythrocytic and exo -erythrocytic stages. Synthetic peptides mimicking P. falciparum receptor binding ligands, human serum albumin, chondroitin sulfate, synthetic polymers, and lipids have been utilized as ligands and decorated onto nanocarriers for specific targeting to parasite-infected erythrocytes. The need of the hour for treatment and prophylaxis against malaria is a broadened horizon that includes multiple targeting strategies against the entry, proliferation, and transmission stages of the parasite. Platform technologies with established pre-clinical safety and efficacy should be translated into clinical evaluation and formulation scale-up. Future development should be directed towards nanovaccines as proactive tools against malaria infection. [Display omitted] • The review highlights various receptors utilized by Plasmodium to infect RBCs. • Review showcases GLUT-1, PfEMP1, glycophorin, semaphorin overexpression on pRBCs. • The review explains natural/synthetic polymers, lipids targeting Plasmodium & pRBC. • Includes the in-vitro and in-vivo efficacy of developed targeted nanoformulations. • Promotes development of novel nanoformulations for unexplored pRBC receptors. [ABSTRACT FROM AUTHOR]